About Diadexus
Diadexus is a company based in San Francisco (United States) founded in 1997 was acquired by Diazyme Laboratories in April 2016.. Diadexus has raised $49.2 million across 3 funding rounds from investors including Burrill and Company, Diazyme Laboratories and Scale Venture Partners. Diadexus offers products and services including Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay. Diadexus operates in a competitive market with competitors including SD Biosensor, GEN inCode, SpectraWAVE, Realview Imaging and Lepu Medical Technology, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Diazyme Laboratories Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$49.2 M (USD)
in 3 rounds
-
Latest Funding Round
$4.5 M (USD), Debt – Conventional
Jun 08, 2010
-
Investors
Burrill and Company
& 5 more
-
Employee Count
Employee Count
-
Acquired by
Diazyme Laboratories
(Apr 01, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Diadexus
Diadexus offers a comprehensive portfolio of products and services, including Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Immunoturbidimetric assay for detecting inflammatory markers
Test for pancreatic function in clinical samples
Fully-automated chemistry analyzer for lab testing
Chemiluminescent assay for cardiovascular markers
Quantitative test for sepsis and infection indicators
Funding Insights of Diadexus
Diadexus has successfully raised a total of $49.2M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $4.5 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Conventional — $4.5M
-
First Round
First Round
(12 Jan 2007)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2010 | Amount | Debt – Conventional - Diadexus | Valuation |
investors |
|
| Feb, 2009 | Amount | Series F - Diadexus | Valuation |
investors |
|
| Jan, 2007 | Amount | Series E - Diadexus | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Diadexus
Diadexus has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Burrill and Company, Diazyme Laboratories and Scale Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital investments are focused on US companies.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Growth & late stage life sciences and tech focused venture capital firm funding companies in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Diadexus
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Diadexus
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Diadexus Comparisons
Competitors of Diadexus
Diadexus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SD Biosensor, GEN inCode, SpectraWAVE, Realview Imaging and Lepu Medical Technology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biosensors for point-of-care diagnostics are developed by SD Biosensor.
|
|
| domain | founded_year | HQ Location |
Genetic and clinical data are integrated for precision cardiac medicines.
|
|
| domain | founded_year | HQ Location |
Photonic imaging diagnostics for cardiovascular disease treatment are provided.
|
|
| domain | founded_year | HQ Location |
3D holographic display solutions for medical imaging are provided.
|
|
| domain | founded_year | HQ Location |
Interventional cardiology devices are developed and marketed globally.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Diadexus
Frequently Asked Questions about Diadexus
When was Diadexus founded?
Diadexus was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Where is Diadexus located?
Diadexus is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Diadexus a funded company?
Diadexus is a funded company, having raised a total of $49.2M across 3 funding rounds to date. The company's 1st funding round was a Series E of $40M, raised on Jan 12, 2007.
What does Diadexus do?
Diadexus develops molecular diagnostic tests for cardiovascular disorders. It currently has two products on the market (under the PLAC trademark) that test Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels. the PLAC Test ELISA kit that assesses the risk of coronary heart disease and ischemic stroke associated with atherosclerosis, while the PLAC Test for Lp-PLA2 Activity that evaluates the risk of coronary heart disease in patients with no prior history of cardiovascular disease. In addition, the company has other biomarker-based tests for heart failure in the pipeline. The lead heart failure biomarker proADM (mid-regional pro-adrenomedullin) has entered formal development on the ELISA platform for a planned 510(k) regulatory submission to the FDA in early 2016. In 2014, Diadexus and Vaxgen entered into a reverse merger agreement, and the combined company was renamed Diadexus.
Who are the top competitors of Diadexus?
Diadexus's top competitors include GEN inCode, SD Biosensor and SpectraWAVE.
What products or services does Diadexus offer?
Diadexus offers Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay.
Who are Diadexus's investors?
Diadexus has 6 investors. Key investors include Burrill and Company, Diazyme Laboratories, Scale Venture Partners, Brookside Capital, and Mosaix Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.